170 related articles for article (PubMed ID: 14871815)
1. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase.
Nakamura H; Suenaga N; Taniwaki K; Matsuki H; Yonezawa K; Fujii M; Okada Y; Seiki M
Cancer Res; 2004 Feb; 64(3):876-82. PubMed ID: 14871815
[TBL] [Abstract][Full Text] [Related]
2. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration.
Kajita M; Itoh Y; Chiba T; Mori H; Okada A; Kinoh H; Seiki M
J Cell Biol; 2001 May; 153(5):893-904. PubMed ID: 11381077
[TBL] [Abstract][Full Text] [Related]
3. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase.
Suenaga N; Mori H; Itoh Y; Seiki M
Oncogene; 2005 Jan; 24(5):859-68. PubMed ID: 15558018
[TBL] [Abstract][Full Text] [Related]
4. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.
Murai T; Miyazaki Y; Nishinakamura H; Sugahara KN; Miyauchi T; Sako Y; Yanagida T; Miyasaka M
J Biol Chem; 2004 Feb; 279(6):4541-50. PubMed ID: 14623895
[TBL] [Abstract][Full Text] [Related]
5. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells.
Egawa N; Koshikawa N; Tomari T; Nabeshima K; Isobe T; Seiki M
J Biol Chem; 2006 Dec; 281(49):37576-85. PubMed ID: 17050542
[TBL] [Abstract][Full Text] [Related]
6. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.
Stamenkovic I; Yu Q
J Invest Dermatol; 2009 Jun; 129(6):1321-4. PubMed ID: 19434087
[TBL] [Abstract][Full Text] [Related]
7. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme.
Toth M; Hernandez-Barrantes S; Osenkowski P; Bernardo MM; Gervasi DC; Shimura Y; Meroueh O; Kotra LP; Gálvez BG; Arroyo AG; Mobashery S; Fridman R
J Biol Chem; 2002 Jul; 277(29):26340-50. PubMed ID: 12004057
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.
Endo K; Takino T; Miyamori H; Kinsen H; Yoshizaki T; Furukawa M; Sato H
J Biol Chem; 2003 Oct; 278(42):40764-70. PubMed ID: 12904296
[TBL] [Abstract][Full Text] [Related]
9. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.
Bernardo MM; Fridman R
Biochem J; 2003 Sep; 374(Pt 3):739-45. PubMed ID: 12755684
[TBL] [Abstract][Full Text] [Related]
10. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
11. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase.
Toth M; Osenkowski P; Hesek D; Brown S; Meroueh S; Sakr W; Mobashery S; Fridman R
Biochem J; 2005 Apr; 387(Pt 2):497-506. PubMed ID: 15560752
[TBL] [Abstract][Full Text] [Related]
12. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
13. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration.
Udayakumar TS; Chen ML; Bair EL; Von Bredow DC; Cress AE; Nagle RB; Bowden GT
Cancer Res; 2003 May; 63(9):2292-9. PubMed ID: 12727852
[TBL] [Abstract][Full Text] [Related]
14. Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation.
Ma J; Tang X; Wong P; Jacobs B; Borden EC; Bedogni B
J Biol Chem; 2014 Mar; 289(12):8442-9. PubMed ID: 24492617
[TBL] [Abstract][Full Text] [Related]
15. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
Anderegg U; Eichenberg T; Parthaune T; Haiduk C; Saalbach A; Milkova L; Ludwig A; Grosche J; Averbeck M; Gebhardt C; Voelcker V; Sleeman JP; Simon JC
J Invest Dermatol; 2009 Jun; 129(6):1471-82. PubMed ID: 18971959
[TBL] [Abstract][Full Text] [Related]
16. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.
Abel S; Hundhausen C; Mentlein R; Schulte A; Berkhout TA; Broadway N; Hartmann D; Sedlacek R; Dietrich S; Muetze B; Schuster B; Kallen KJ; Saftig P; Rose-John S; Ludwig A
J Immunol; 2004 May; 172(10):6362-72. PubMed ID: 15128827
[TBL] [Abstract][Full Text] [Related]
17. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
18. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
19. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain.
Mori H; Tomari T; Koshikawa N; Kajita M; Itoh Y; Sato H; Tojo H; Yana I; Seiki M
EMBO J; 2002 Aug; 21(15):3949-59. PubMed ID: 12145196
[TBL] [Abstract][Full Text] [Related]
20. MT1-MMP and ADAM10/17 exhibit a remarkable overlap of shedding properties.
Werny L; Grogro A; Bickenbach K; Bülck C; Armbrust F; Koudelka T; Pathak K; Scharfenberg F; Sammel M; Sheikhouny F; Tholey A; Linder S; Becker-Pauly C
FEBS J; 2023 Jan; 290(1):93-111. PubMed ID: 35944080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
